Skip to main content
Premium Trial:

Request an Annual Quote

Martin Madaus, Francis Lunger, Nancy Gillet, Glenn Kerkhof, Paul Oskar, and Christopher Perkin

Premium

Millipore announced last week that its new president and CEO, Martin Madaus, will start on Jan. 1, 2005. As previously announced, he is assuming the roles of president and CEO from Francis Lunger, who will remain as chairman of the board until March 1, 2005.


In connection with its integration with Inveresk Research Group, Charles River Laboratories has promoted Nancy Gillet to the post of senior vice president and president of global preclinical services. Gillet succeeds Michael Ankcorn, who is retiring from the firm effective Dec. 31. She previously served as corporate vice president and president of US preclinical services.

In addition, Charles River announced that Glenn Kerkhof was named interim president of global clinical services, succeeding Alistair McEwan, who left the company last week. Paul Oskar was promoted to general manager and president of US preclinical services from his previous position as general manager, DDS Worcester division. Christopher Perkin, the firm’s current chief operating officer of CTBR, was named general manager and president of Canadian preclinical services.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.